Skip to main content

Table 4 Interaction of 2-DG (1 mM) with c-MYC-inhibitor (2 µM; a), LY294002 (5 µM; b), Rapamycin (200 nM; c), PD98059 (5 µM; d) and SB203580 (5 µM; e) in the three lymphoma cell lines

From: Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability

a cell line 2-DG
1 mM
c-MYC-inh.
2 µM
2-DG + c-MYC-inh. CI
BJAB 89.6 ± 7.4 91.0 ± 7.7 57.7 ± 4.8 1.41 syn.
OCI-LY3 81.0 ± 6.6 85.4 ± 7.3 56.3 ± 5.5 1.23 syn.
SU-DHL-6 84.0 ± 6.3 86.3 ± 6.4 57.9 ± 5.1 1.25 syn.
b cell line 2-DG
1 mM
LY294002
5 µM
2-DG + Y294002 CI
BJAB 88,1 ± 7.0 84.6 ± 7.0 47.2 ± 3.5 1.60 syn.
OCI-LY3 79.0 ± 7.3 73.7 ± 6.6 42.6 ± 4.6 1.37 syn.
SU-DHL-6 83.5 ± 6.4 87.9 ± 8.1 38.2 ± 3.1 1.92 syn.
c cell line 2-DG
1 mM
Rapamycin
200 nM
2-DG + Rapamycin CI
BJAB 90.7 ± 6.8 90.4 ± 8.3 58.2 ± 3.7 1.41 syn.
OCI-LY3 80.5 ± 6.4 88.9 ± 7.6 69.5 ± 5.0 1.03 add.
SU-DHL-6 82.5 ± 7.6 91.6 ± 7.9 47.8 ± 3.4 1.58 syn
d cell line 2-DG
1 mM
PD98059
5 µM
2-DG + PD98059 CI
BJAB 90.3 ± 8.4 103.7 ± 9.2 95.7 ± 7.7 0.98 add.
OCI-LY3 81.5 ± 6.8 98.2 ± 8.5 75.3 ± 5.6 1.06 syn.
SU-DHL-6 81.5 ± 5.8 99.4 ± 7.8 77.9 ± 6.5 1.04 add.
e cell line 2-DG
1 mM
SB203580
5 µM
2-DG + SB203580 CI
BJAB 91.4 ± 6.7 102.6 ± 9.0 83.5 ± 7.0 1.12 syn.
OCI-LY3 80.8 ± 7.4 97.8 ± 7.6 63,5 ± 5.3 1.24 syn.
SU-DHL-6 79.6 ± 5.7 104.3 ± 8.4 54.1 ± 4.5 1.53 syn.
  1. MTT assays were performed to determine the viability of cells after incubation with one compound alone or in combination. Cl values were calculated according to the method of Drewinko et al. (see “Methods”), where Cl > 1.05 indicates synergism (syn.), 0.95 ≤ Cl ≤ 1.05 indicates additivity (add.) and Cl < 0.95 indicates antagonism